Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
Global pharma companies that have publicly announced Trump drug pricing agreements
02:59pm, Thursday, 02'nd Apr 2026
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye
The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income
08:10am, Thursday, 02'nd Apr 2026
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees.
Cyr Financial Inc. Takes Position in AbbVie Inc. $ABBV
05:40am, Thursday, 02'nd Apr 2026
Cyr Financial Inc. purchased a new position in shares of AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
Compagnie Lombard Odier SCmA Raises Holdings in AbbVie Inc. $ABBV
05:06am, Thursday, 02'nd Apr 2026
Compagnie Lombard Odier SCmA lifted its position in shares of AbbVie Inc. (NYSE: ABBV) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional i
Bourgeon Capital Management LLC Takes Position in AbbVie Inc. $ABBV
04:06am, Wednesday, 01'st Apr 2026
Bourgeon Capital Management LLC bought a new position in shares of AbbVie Inc. (NYSE: ABBV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commissi
Will AbbVie's Oncology Drugs Aid Top Line in 2026?
10:32am, Tuesday, 31'st Mar 2026
ABBV's oncology lineup faces a 2026 sales dip despite rising contributions from newer drugs, as pricing pressure on Imbruvica weighs on growth.
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
08:05am, Tuesday, 31'st Mar 2026
First-Time Users Can Claim $400 Off Their First Body Contouring Treatment. * † IRVINE, Calif.
AbbVie to Host First-Quarter 2026 Earnings Conference Call
08:00am, Tuesday, 31'st Mar 2026
NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens.
Financial Planning Hawaii Inc. Invests $2.90 Million in AbbVie Inc. $ABBV
05:10am, Tuesday, 31'st Mar 2026
Financial Planning Hawaii Inc. bought a new stake in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The i
Brookstone Capital Management Sells 6,299 Shares of AbbVie Inc. $ABBV
04:37am, Tuesday, 31'st Mar 2026
Brookstone Capital Management cut its stake in shares of AbbVie Inc. (NYSE: ABBV) by 6.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC
Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
03:35am, Monday, 30'th Mar 2026
Beacon Investment Advisory Services Inc. grew its stake in shares of AbbVie Inc. (NYSE: ABBV) by 4.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. Th
Chesley Taft & Associates LLC Has $5.20 Million Stake in AbbVie Inc. $ABBV
05:36am, Sunday, 29'th Mar 2026
Chesley Taft and Associates LLC raised its position in AbbVie Inc. (NYSE: ABBV) by 18.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Ex
Eastern Bank Boosts Stake in AbbVie Inc. $ABBV
04:50am, Sunday, 29'th Mar 2026
Eastern Bank grew its stake in shares of AbbVie Inc. (NYSE: ABBV) by 0.7% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 380,469
AbbVie: Strong 2026 Outlook, Expect Dividend Increases
02:42pm, Friday, 27'th Mar 2026
AbbVie remains well-positioned for long-term growth, despite recent share price consolidation and near-term geopolitical headwinds. I expect Skyrizi and Rinvoq to drive double-digit revenue growth in
Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritis Data includes real-world evidence of m
